… 2025 and declared a third-quarter 2025 dividend. First … Directors has approved a third-quarter 2025 dividend of … cash flow minus capital expenditures) was $58.1 … and-declares-third-quarter-2025-dividend-302436657.html SOURCE West Pharmaceutical Services, …

… earnings beginning in the third quarter. And in the Performance … will start to be accretive third quarter, fourth quarter. Capacity … energy, home care, and pharma end markets. Data centers, … approaching a big capital expenditure for a lifetime extension …

… a clinical stage global pharmaceutical company that develops and … operating expenses and capital expenditure requirements for at least … Form 10-Q for its third quarter of fiscal year 2024. … operating expenses and capital expenditure requirements for at least …

… to 83 in the third quarter. This was disclosed in … room for unverified tax expenditure figures in different quarters. … when analysing the Tax Expenditures in terms of … include manufacturing, solid material, pharmaceuticals, information and communication, trade, …

… induction results expected in Q3 2025 PARIS, France … data expected in the third quarter of 2025. Marc … operating expenses and capital expenditure requirements. Special consideration … the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC …

… accrual recorded during the third quarter of 2024. For information … accrual recorded during the third quarter of 2024. The … obtain medical supplies or pharmaceuticals at favorable prices; … facilities or other capital expenditures; our ability to successfully …

… July 24, 2025) October 22 Third Quarter 2025 results (webcast October 23 … on consensus forecasts from Evaluate Pharma, which compiles analyst reports for … ) (3,742) Purchase of and expenditure in intangible fixed assets (155 …

… .5 billion and capital expenditures are expected to be approximately … we saw both in the third quarter and fourth quarter last … being the best quarter, Q3 slightly lower than that, … That business is primarily serving pharmaceutical companies, CROs. It serves …

… colitis expected in Q3 2025 PARIS, France … expenses and capital expenditure requirements. Special consideration … of clinical and pharmaceutical development, including further … the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, …

… TGT Teradyne TER Teva Pharmaceutical Industries TEVA US … activity from large pharma customers, including capital expenditure on instruments, … a rough second and third quarter, but a recovery in … Teradyne here. Teva Pharmaceutical Industries Shares of Teva …